Comparison of Pulse Wave and Blood Pressure Measurements Before, During and After Ergometry in Healthy Men

August 6, 2019 updated by: ARCIM Institute Academic Research in Complementary and Integrative Medicine

Comparison of Pulse Wave and Blood Pressure Parameters Before, During and After Exercise Ergometry in Healthy Male Subjects - a Randomized, Controlled, Single-blind Study

The objective of this randomized, controlled single blind study is to compare pulse wave and blood pressure measurements before, during and after exercise ergometry in healthy male subjects.

Study Overview

Status

Completed

Conditions

Healthy Male Subjects

Intervention / Treatment

Detailed Description

In a randomized single-blind study design the investigators explore how well blood pressure parameters calculated using a Pulse Transit Time-based method (device: SOMNOtouchTM RESP) match blood pressure parameters measured by a classic upper arm blood pressure cuff (Mobil-O-Graph® PWA) under standardized load conditions (ergometry).

In 30 healthy male subjects (age 18 - 40 years), cardiovascular parameters before, during and after a standardized load on a bicycle ergometer (half-lying position) are recorded with three different devices (Mobil-O-Graph® PWA versus SOMNOtouchTM RESP versus GeTeMed Vitaguard 3100) and compared.

Primary outcome is the difference of the systolic blood pressure values between the devices Mobil-O-Graph® PWA versus SOMNOtouchTM RESP during the three phases.

The Mobil-O-Graph® PWA blood pressure cuff is applied randomized to the arm with the previously determined higher or lower systolic blood pressure mean difference. The subjects are blinded to the results of the measurements during ergometry.

After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest period. Measurements are taken every two minutes with the Mobil-O-Graph® PWA; data acquisition with the SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 devices takes place continuously over a total duration of 72 minutes.

Study Type

Interventional

Enrollment (Actual)

Phase

Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Germany
- Baden Württemberg
  - Filderstadt, Baden Württemberg, Germany, 70794
    - Arcim Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

Signed informed consent
Healthy at the time of the examinations
Inconspicuous anamnesis regarding cardiovascular diseases and bronchial asthma
resting heart rate 50 to 100 beats per minute
Normal blood pressure or appropriately treated and controlled hypertension (systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg)

Exclusion Criteria:

Acute or chronic (especially cardiovascular) diseases, including cardiac arrhythmia and vegetative regulatory disorders (recorded via anamnesis)
Taking allopathic medication: digitalis, beta blockers, antiarrhythmics
Bronchial asthma (recorded by anamnesis)
Alcohol abuse
Heart diseases NYHA class IV
Blood pressure side difference ≥ 10mmHg
Fever (> 37,5°C)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Single

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Higher Blood Pressure Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H	Other: Ergometry H After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period. Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter). SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure.
Experimental: Lower Blood Pressure Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L	Other: Ergometry L After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period. Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter). SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure.

Participant Group / Arm

Intervention / Treatment

Experimental: Higher Blood Pressure

Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H

Other: Ergometry H

After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.

Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).

SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure.

Experimental: Lower Blood Pressure

Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L

Other: Ergometry L

After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.

Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).

SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of the systolic blood pressure Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Primary outcome is the difference of the systolic blood pressure values between the devices Mobil-O-Graph® PWA versus SOMNOtouchTM RESP during the three phases	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ARCIM Institute Academic Research in Complementary and Integrative Medicine

Collaborators

Universität Tübingen

Investigators

Study Director: Jan Vagedes, MD, ARCIM Institute, Im Haberschlai 7, 70794 Filderstadt, Germany

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 28, 2019

Primary Completion (Actual)

May 22, 2019

Study Completion (Actual)

May 22, 2019

Study Registration Dates

First Submitted

December 27, 2018

First Submitted That Met QC Criteria

December 28, 2018

First Posted (Actual)

January 2, 2019

Study Record Updates

Last Update Posted (Actual)

August 7, 2019

Last Update Submitted That Met QC Criteria

August 6, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

ERG_02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Male Subjects

Hoffmann-La Roche

Completed

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

Healthy Male Subjects

Australia, New Zealand
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Mass Balance and Biotransformation Study of [14C]DBPR108 in Human

Healthy Male Subjects

China
Celltrion

Completed

A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

Healthy Male Subjects

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib

Healthy Male Subjects

China
JHL Biotech, Inc.

Completed

A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

Healthy Male Subjects

Bulgaria
Pfizer

Completed

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

Healthy Male Subjects

Netherlands
Hanlim Pharm. Co., Ltd.

Completed

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)

Healthy Male Subjects

Korea, Republic of
Hanlim Pharm. Co., Ltd.

Completed

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects

Healthy Male Subjects

Korea, Republic of
Bio-ker S.r.l.
Cross Research S.A.; Nerviano Medical Sciences; AAI Deutschland GmbH & Co. KG; Gife...

Completed

Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®

Healthy Male Subjects

Switzerland

Clinical Trials on Ergometry H

ARCIM Institute Academic Research in Complementary...
Universität Tübingen

Completed

Comparison of Pulse Wave and Blood Pressure Measurements Before, During and After Ergometry in Healthy Women

Healthy Female Subjects

Germany
Universitätsklinikum Hamburg-Eppendorf
Deutsche Multiple Sklerose Gesellschaft Hamburg

Unknown

Armergometry to Improve Mobility in MS (AMBOS)

Multiple Sclerosis

Germany
Royal College of Surgeons, Ireland
Beaumont Hospital; Post Polio Support Group Ireland

Completed

Arm Cycling to Improve Fitness in Polio Survivors

Postpoliomyelitis Syndrome

Ireland
Wake Forest University Health Sciences
National Institute on Aging (NIA); National Center for Advancing Translational...

Active, not recruiting

A Study Promoting Critical Illness Recovery in the Elderly (ASPIRE)

Critical Illness | Acute Respiratory Distress Syndrome | Critical Care

United States
Precordior Ltd
Paavo Nurmi Centre

Recruiting

Gyrocardiography- A New Non-invasive Cardiac Measurement Method to Measure Exercise Capacity and Cardiorespiratory Fitness

Healthy

Finland
Technical University of Madrid

Completed

Lactate Profile and Fat Oxidation During Exercise (LacFat)

Energy Metabolism

Spain
Riphah International University

Completed

Pursed Lip Breathing With Arm Ergometry After Chin Supported Position in COPD Patients.

COPD

Pakistan
National University Hospital, Singapore

Active, not recruiting

Feeding With Indirect Calorimetry and Cycling in the Elderly (FICE)

Muscular Atrophy | Critical Care | Exercise Therapy | Calorimetry, Indirect

Singapore
University of Leicester
National Institute for Health Research, United Kingdom; National Health Service...

Completed

Arming Health: Can Breaking up Restful Sitting Time With Upper Body Contractile Activity Regulate Metabolic Health. (AYH)

Diabetes

United Kingdom
Medical University of Vienna

Completed

Physical Recovery After Laparoscopic vs. Open Liver Resection

Liver Diseases | Postoperative Complications | Surgery | Physical Stress

Austria

Outcome Measure	Measure Description	Time Frame
Diastolic Blood Pressure (SOMNOtouchTM RESP) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Diastolic Blood Pressure (mm Hg) measured with the SOMNOtouchTM RESP device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Mean Arterial Blood Pressure (SOMNOtouchTM RESP) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Mean Arterial Blood Pressure (mm Hg) measured with the SOMNOtouchTM RESP device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Pulse Pressure (SOMNOtouchTM RESP) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Pulse Pressure (mm Hg) measured with the SOMNOtouchTM RESP device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Heartrate (SOMNOtouchTM RESP) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Heartrate (beats per minute, bpm) measured with the SOMNOtouchTM RESP device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Oxygen saturation (SpO2, SOMNOtouchTM RESP) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Oxygen saturation (% SpO2) measured with the SOMNOtouchTM RESP device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Pulse-Transit-Time (PTT, SOMNOtouchTM RESP) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Pulse-Transit-Time (PTT, ms) measured with the SOMNOtouchTM RESP device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Systolic Blood Pressure measured with the device Mobil-O-Graph® PWA Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Systolic Blood Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Diastolic Blood Pressure measured with the device Mobil-O-Graph® PWA Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Diastolic Blood Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Mean Arterial Blood Pressure measured with the device Mobil-O-Graph® PWA Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Mean Arterial Blood Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Pulse Pressure measured with the device Mobil-O-Graph® PWA Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Pulse Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Heartrate (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Heartrate (beats per minute, bpm) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Puls Pressure Amplification (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Puls Pressure Amplification measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Stroke Volume (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Stroke Volume (ml) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Cardiac output (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Cardiac output (l/min) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Vascular Resistance (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Vascular Resistance (s*mmHg/ml) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Cardiac Index (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Cardiac Index (l/min*1/m2) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Augmentation Pressure (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Augmentation Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Reflection Coefficient (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Reflection Coefficient (%) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Pulse Wave Velocity (PWV) (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Pulse Wave Velocity (PWV, m/s) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Systole Time (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Systole Time (s) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Tmax-forward (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Tmax-forward (s) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Tmax-backward (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Tmax-backward (s) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Forward Pressure (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Forward Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Backward Pressure (Mobil-O-Graph® PWA) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Backward Pressure (mmHg) measured with the Mobil-O-Graph® PWA device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Pulse Transit Time (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Pulse Transit Time (PTT, ms) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Perfusion Index (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Perfusion Index (PI) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
Peak to Peak Time (PPT) (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Peak to Peak Time (PPT, ms) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
SlopeInW1 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	SlopeInW1 measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
SlopeInW2 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	SlopeInW2 measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
SlopeInW3 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	SlopeInW3 measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
SlopeInW4 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	SlopeInW4 measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
StiffnessIndex (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	StiffnessIndex measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
ReflectionIndex (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	ReflectionIndex measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
TimeTX (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	TimeTX (ms) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
TimeTY (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	TimeTY (ms) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
QuotTYTX (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	QuotTYTX measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
AreaAX (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	AreaAX measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
AreaAY (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	AreaAY measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
QuotAYAX (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	QuotAYAX measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
AreaAV (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	AreaAV measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
AreaAW (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	AreaAW measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
QuotAWAV (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	QuotAWAV measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
QuotTVTW (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	QuotTVTW measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
TimeTV (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	TimeTV (ms) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
TimeTW (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	TimeTW (ms) measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
MinT1 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Minimum of the pulse wave measured with the GeTeMed Vitaguard 3100 device at the beginning of the first peak	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
MinT2 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Minimum of the pulse wave measured with the GeTeMed Vitaguard 3100 device at the beginning of the second peak	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
MaxT1 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Maximum of the pulse wave measured with the GeTeMed Vitaguard 3100 device at the maximum of the first peak	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
MaxT2 (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Maximum of the pulse wave measured with the GeTeMed Vitaguard 3100 device at the maximum of the second peak	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min
QuotHRRespRate (GeTeMed Vitaguard 3100) Time Frame: Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min	Quotient of heart and respiratory rates measured with the GeTeMed Vitaguard 3100 device	Physiological parameters are measured continuously (SOMNOtouchTM RESP) and every 2 min (Mobil-O-Graph©PWA) for a total duration of 72 min

Comparison of Pulse Wave and Blood Pressure Measurements Before, During and After Ergometry in Healthy Men

Comparison of Pulse Wave and Blood Pressure Parameters Before, During and After Exercise Ergometry in Healthy Male Subjects - a Randomized, Controlled, Single-blind Study

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Investigators

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Healthy Male Subjects

Clinical Trials on Ergometry H

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations